» Articles » PMID: 23623998

Community-based Lifestyle Modification Programme for Non-alcoholic Fatty Liver Disease: a Randomized Controlled Trial

Abstract

Background & Aims: Healthy lifestyle is the most important management of non-alcoholic fatty liver disease (NAFLD). This study aimed at assessing the efficacy of a community-based lifestyle modification programme in the remission of NAFLD.

Methods: This was a parallel group, superiority, randomized controlled trial. 154 adults with NAFLD identified during population screening were randomized to participate in a dietitian-led lifestyle modification programme at 2 community centres or receive usual care for 12 months. The primary outcome was remission of NAFLD at month 12 as evidenced by intrahepatic triglyceride content (IHTG) of less than 5% by proton-magnetic resonance spectroscopy.

Results: 74 patients in the intervention group and 71 patients in the control group completed all study assessments. In an intention-to-treat analysis of all 154 patients, 64% of the patients in the intervention group and 20% in the control group achieved remission of NAFLD (difference between groups 44%; 95% CI 30-58%; p<0.001). The mean (SD) changes in IHTG from baseline to month 12 were -6.7% (6.1%) in the intervention group and -2.1% (6.4%) in the control group (p<0.001). Body weight decreased by 5.6 (4.4) kg and 0.6 (2.5) kg in the two groups, respectively (p<0.001). While 97% of patients with weight loss of more than 10% had remission of NAFLD, 41% of those with weight loss of 3.0-4.9% could also achieve the primary outcome.

Conclusions: The community-based lifestyle modification programme is effective in reducing and normalizing liver fat in NAFLD patients.

Citing Articles

Metabolic dysfunction-associated steatotic liver disease in adults.

Huang D, Wong V, Rinella M, Boursier J, Lazarus J, Yki-Jarvinen H Nat Rev Dis Primers. 2025; 11(1):14.

PMID: 40050362 DOI: 10.1038/s41572-025-00599-1.


The Safety and Efficacy of Dietary Epigallocatechin Gallate Supplementation for the Management of Obesity and Non-Alcoholic Fatty Liver Disease: Recent Updates.

Yan R, Cao Y Biomedicines. 2025; 13(1).

PMID: 39857788 PMC: 11762999. DOI: 10.3390/biomedicines13010206.


Estimated Burden of Metabolic Dysfunction-Associated Steatotic Liver Disease in US Adults, 2020 to 2050.

Le P, Tatar M, Dasarathy S, Alkhouri N, Herman W, Taksler G JAMA Netw Open. 2025; 8(1):e2454707.

PMID: 39821400 PMC: 11742522. DOI: 10.1001/jamanetworkopen.2024.54707.


Correlation between metabolic dysfunction-associated steatotic liver disease and subclinical coronary atherosclerosis in eastern China.

Ma G, Xu G, Huang H Diabetol Metab Syndr. 2025; 17(1):16.

PMID: 39815332 PMC: 11736921. DOI: 10.1186/s13098-025-01577-z.


Fibrosis-4 index is closely associated with future development of hypertension in the Japanese general population.

Yamashita S, Takase H, Kawakatsu N, Hayashi K, Kin F, Isogaki T Hypertens Res. 2024; 48(2):796-804.

PMID: 39639128 DOI: 10.1038/s41440-024-02028-4.